Skip to main content

Table 2 Engraftment and GVHD

From: The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party

  HLA 10/10 HLA 9/10 HLA 8/10 p value
Total number of patients 2567 723 108  
Engraftment, n (%) 2458 (97.3 %) 678 (96.3 %) 101 (97.12 %) 0.313
 No engraftment, n (%) 67 (2.7 %) 26 (3.7 %) 3 (2.9 %)  
 Missing, n 42 19 5  
Median time ANC >0.5 G/L (days, range) 16 (0–103) 16 (1–165) 15.5 (1–33) 0.538
Acute GVHD,     
 Grade 0–I, n (%) 1826 (74.4 %) 469 (67.2 %) 67 (65.7 %) 0.0002
 Grades II–IV, n (%) 629 (25.6 %) 229 (32.8 %) 35 (34.3 %)  
 Grades III–IV, n (%) 234 (9.5 %) 90 (12.9 %) 11 (10.8 %) 0.035
 Missing, n 75 21 3  
Chronic GVHDa     
 All grades 35.0 % [32.9–37.2] 35.1 % [31.2–39] 44.4 % [33.6–54.6] 0.138
 Extensive 17.1 % [15.4–18.9] 15.2 % [12.3–18.5] 26.1 % [16.8–36.4] 0.047
 Limited, n 369 109 14  
 Extensive, n 324 80 21  
 Missing, n 38 18 5  
  1. GVHD graft-versus-host disease
  2. aTwo-year cumulative incidence